ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Attenuated Bacteria-Based Tumor Therapy: Clinical Application Risks, Marketing Approval Restrictions, and Coping Strategies.
Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Microbial Signals in Cancer: Dissecting Host-Microbiota-Tumor Interactions and Potential Therapeutic Strategy.MedComm · 2026Review
- Bacterial-based cancer therapy: mechanisms and therapeutic advances.Molecular biomedicine · 2026Review
- What Does Bacteria Have to Do with Cancer? The Influence of the Body's Microbiota on Cancer in Cats and Dogs.International journal of molecular sciences · 2026Review
- Radiomics: Current Applications and Future Directions.MedComm · 2026Review
- Oncolytic bacteria therapy for malignant glioma.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Bacteria-based cancer therapy is a promising cancer treatment strategy that utilizes genetically engineered attenuated bacteria to specifically target tumor tissues, directly kill cancer cells, or activate the host's immune response. Engineering modifications of attenuated bacteria can achieve more effective anti-tumor effects, and consequently, a number of clinical trials have been carried out. However, the clinical translation of attenuated bacteria faces multiple challenges, including safety risks, fluctuating therapeutic efficacy, difficulties in vivo monitoring, complex production quality control, and lack of regulatory approval standards. This review mainly summarizes five aspects of bacterial cancer therapy: the safety risks and attenuation strategies, the regulation of therapeutic stability, bacterial in vivo imaging technologies, the optimization of bacterial production processes, and market approval pathways. It aims to precisely control bacterial behavior through genetic circuits and enable real-time monitoring of the treatment process by means of multimodal imaging, ultimately promoting the clinical translation of attenuated bacterial therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.